Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ebiom.2020.103153 http://scihub22266oqcxt.onion/10.1016/j.ebiom.2020.103153 33279857!7711201!33279857     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33279857&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       EBioMedicine 2021 ; 63 (?): 103153 Nephropedia Template TP {{tp|p=33279857|t=2021. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model |pdf=|usr=}}{{33279857}} gab.com Text Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model JO: EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=33279857 #FOAvip BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge economic burden. Like all respiratory viruses, SARS-CoV-2 initiates infection in the upper respiratory tract (URT). Infected individuals are often asymptomatic, yet highly infectious and readily transmit virus. A therapy that restricts initial replication in the URT has the potential to prevent progression of severe lower respiratory tract disease as well as limiting person-to-person transmission. METHODS: SARS-CoV-2 Victoria/01/2020 was passaged in Vero/hSLAM cells and virus titre determined by plaque assay. Challenge virus was delivered by intranasal instillation to female ferrets at 5.0 x 10(6) pfu/ml. Treatment groups received intranasal INNA-051, developed by Ena Respiratory. SARS-CoV-2 RNA was detected using the 2019-nCoV CDC RUO Kit and QuantStudio 7 Flex Real-Time PCR System. Histopathological analysis was performed using cut tissues stained with haematoxylin and eosin (H&E). FINDINGS: We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat. After 5 days post-exposure to SARS-CoV-2, INNA-051 significantly reduced virus in throat swabs (p=<0.0001) by up to a 24 fold (96% reduction) and in nasal wash (p=0.0107) up to a 15 fold (93% reduction) in comparison to untreated animals. INTERPRETATION: The results of our study support clinical development of a therapy based on prophylactic TLR2/6 innate immune activation in the URT, to reduce SARS-CoV-2 transmission and provide protection against COVID-19. FUNDING: This work was funded by Ena Respiratory, Melbourne, Australia. Twit Text FOAVip Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model ????EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=33279857 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33279857 #FOAvip English Wikipedia <ref>{{Cite pmid|33279857}}</ref> Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model #MMPMID33279857 Proud PC; Tsitoura D; Watson RJ; Chua BY; Aram MJ; Bewley KR; Cavell BE; Cobb R; Dowall S; Fotheringham SA; Ho CMK; Lucas V; Ngabo D; Rayner E; Ryan KA; Slack GS; Thomas S; Wand NI; Yeates P; Demaison C; Zeng W; Holmes I; Jackson DC; Bartlett NW; Mercuri F; Carroll MW EBioMedicine 2021[Jan]; 63 (?): 103153 PMID33279857show ga BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge economic burden. Like all respiratory viruses, SARS-CoV-2 initiates infection in the upper respiratory tract (URT). Infected individuals are often asymptomatic, yet highly infectious and readily transmit virus. A therapy that restricts initial replication in the URT has the potential to prevent progression of severe lower respiratory tract disease as well as limiting person-to-person transmission. METHODS: SARS-CoV-2 Victoria/01/2020 was passaged in Vero/hSLAM cells and virus titre determined by plaque assay. Challenge virus was delivered by intranasal instillation to female ferrets at 5.0 x 10(6) pfu/ml. Treatment groups received intranasal INNA-051, developed by Ena Respiratory. SARS-CoV-2 RNA was detected using the 2019-nCoV CDC RUO Kit and QuantStudio 7 Flex Real-Time PCR System. Histopathological analysis was performed using cut tissues stained with haematoxylin and eosin (H&E). FINDINGS: We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat. After 5 days post-exposure to SARS-CoV-2, INNA-051 significantly reduced virus in throat swabs (p=<0.0001) by up to a 24 fold (96% reduction) and in nasal wash (p=0.0107) up to a 15 fold (93% reduction) in comparison to untreated animals. INTERPRETATION: The results of our study support clinical development of a therapy based on prophylactic TLR2/6 innate immune activation in the URT, to reduce SARS-CoV-2 transmission and provide protection against COVID-19. FUNDING: This work was funded by Ena Respiratory, Melbourne, Australia. |*Virus Shedding[MESH] |Administration, Intranasal[MESH] |Animals[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/pathology[MESH] |Disease Models, Animal[MESH] |Female[MESH] |Ferrets[MESH] |Immunity, Innate[MESH] |Lipopeptides/*administration & dosage/chemistry/pharmacology[MESH] |Nasal Cavity/pathology/virology[MESH] |Pharynx/pathology/virology[MESH] |RNA, Viral/metabolism[MESH] |Real-Time Polymerase Chain Reaction[MESH] |Respiratory System/pathology/*virology[MESH] |SARS-CoV-2/genetics/isolation & purification/*pathogenicity[MESH] |Toll-Like Receptor 2/*agonists[MESH] |Toll-Like Receptor 6/*agonists[MESH]Prophylactic intranasal administration of a TLR2/6 agonist reduces upp(epmc).pdf DeepDyve Pubget Overpricing